vinorelbine
vinorelbine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hodgkin Lymphoma、Relapsed or Refractory Hodgkin Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
6 项
已进入 III/IV 期
19 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Memorial Sloan Kettering Cancer Center
- Brigham and Women's Hospital
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Fudan University
- University of Birmingham
- Jian Chen
- European Institute of Oncology
- Sun Yat-sen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、澳大利亚、奥地利、比利时、Czechia、丹麦、法国、Greece、爱尔兰、Israel、意大利
正在招募患者的 vinorelbine 研究
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
早期 I 期招募中美国NCT05553782TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
III 期招募中中国NCT07047365SNF Platform Study of HR+/ HER2-advanced Breast Cancer
II 期招募中中国NCT05594095FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
II 期招募中中国NCT06311981Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
II 期招募中意大利NCT06690840Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
III 期招募中中国NCT07088263Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
不适用招募中中国NCT07041320Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
III 期招募中中国NCT06081959Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
III 期招募中中国NCT06255392Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
II 期招募中中国NCT06489808Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
II 期招募中中国NCT06875076Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
II 期招募中中国NCT06649331A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
I 期 / II 期招募中中国NCT06202261Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
I 期招募中美国NCT04701645LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
不适用招募中美国NCT06576635Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
III 期招募中法国NCT06908993European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
I 期 / II 期招募中丹麦法国意大利荷兰NCT02813135Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
不适用招募中中国NCT05856383Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
II 期招募中美国NCT06023641Arsenous Acid for Refractory Triple-Negative Breast Cancer
II 期招募中中国NCT06678048ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
II 期招募中美国加拿大法国意大利NCT07007559Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
II 期招募中中国NCT06839560JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
III 期招募中中国NCT06079983
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。